Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Self-copying RNA vaccine wins first full approval: what’s next?

Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making.
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed  Google Scholar

The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a pivotal advance.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 624, 236-237 (2023)

doi: https://doi.org/10.1038/d41586-023-03859-w

References

  1. Oda, Y. Preprint at medRxiv https://doi.org/10.1101/2023.07.13.23292597 (2023).

  2. Komori, M. et al. Preprint at bioRxiv https://doi.org/10.1101/2023.11.01.565056 (2023).

  3. McGee, J. E. et al. Preprint at bioRxiv https://doi.org/10.1101/2023.09.15.557994 (2023).

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links